Statements (35)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
organic arsenical compound |
| gptkbp:administeredBy |
intravenous injection
|
| gptkbp:ATCCode |
P01CD01
|
| gptkbp:CASNumber |
494-79-1
|
| gptkbp:chemicalFormula |
C12H15AsN6OS2
|
| gptkbp:contraindication |
hypersensitivity to arsenic compounds
|
| gptkbp:developedBy |
gptkb:Aventis
|
| gptkbp:discoveredIn |
1949
|
| https://www.w3.org/2000/01/rdf-schema#label |
melarsoprol
|
| gptkbp:isA |
antineoplastic agent
arsenic-containing drug |
| gptkbp:KEGGID |
D02368
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:MeSH_ID |
D008557
|
| gptkbp:molecularWeight |
398.34 g/mol
|
| gptkbp:origin |
synthesized from dimercaprol and melarsen oxide
|
| gptkbp:otherName |
gptkb:Mel_B
arsobal |
| gptkbp:PubChem_CID |
4057
6706 |
| gptkbp:riskFactor |
high toxicity
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
gptkb:encephalopathy
fever vomiting hypertension rash polyneuropathy |
| gptkbp:UNII |
8U6A1WP42K
|
| gptkbp:usedFor |
treatment of African trypanosomiasis
treatment of sleeping sickness |
| gptkbp:usedIn |
late-stage Trypanosoma brucei infection
|
| gptkbp:bfsParent |
gptkb:Trypanosomiasis
|
| gptkbp:bfsLayer |
5
|